{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+Dementia&page=10",
    "query": {
      "condition": "Alzheimer Disease Dementia",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 1989,
    "total_pages": 199,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+Dementia&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+Dementia&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:35:08.770Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07413744",
      "title": "The Gut - PRO Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Probiotic",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-10",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07413744"
    },
    {
      "nct_id": "NCT04296565",
      "title": "Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "WATER+CT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 121,
      "start_date": "2022-01-03",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04296565"
    },
    {
      "nct_id": "NCT01766336",
      "title": "A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Group 1 ELND005",
          "type": "DRUG"
        },
        {
          "name": "Group 2 ELND005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "50 Years to 95 Years"
      },
      "enrollment_count": 296,
      "start_date": "2013-01",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766336"
    },
    {
      "nct_id": "NCT07697664",
      "title": "Moving Yourself in Space and Time: MYSTIC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease (PD)",
        "Alzheimer's Disease (AD) and Related Disorders",
        "Older Adults (60 - 85 Years Old)"
      ],
      "interventions": [
        {
          "name": "Complex Rhythmic Movement Sequences (CRMS) Sessions",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 210,
      "start_date": "2022-03-25",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07697664"
    },
    {
      "nct_id": "NCT03367403",
      "title": "A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Donanemab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY3202626",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 272,
      "start_date": "2017-12-18",
      "completion_date": "2021-09-21",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03367403"
    },
    {
      "nct_id": "NCT00065169",
      "title": "Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 138,
      "start_date": "2000-11",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065169"
    },
    {
      "nct_id": "NCT05082883",
      "title": "Cognitive Screening Made Easy for PCPs",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease",
        "Mild Cognitive Impairment",
        "Cognitive Decline"
      ],
      "interventions": [
        {
          "name": "Risk Assessment Cognitive Screening",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Texas at Austin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2021-08-13",
      "completion_date": "2023-05-01",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05082883"
    },
    {
      "nct_id": "NCT00948766",
      "title": "Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 4.6 mg/24 h (5 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 9.5 mg/24 h (10 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 13.3 mg/24 h (15 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2009-07",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 93,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948766"
    },
    {
      "nct_id": "NCT00151502",
      "title": "To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 600,
      "start_date": "2002-11",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 40,
      "location_summary": "Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00151502"
    },
    {
      "nct_id": "NCT01165554",
      "title": "Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Fibrillarab Levels"
      ],
      "interventions": [
        {
          "name": "[18F] Flutemetamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2010-05",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-15T17:35:08.770Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165554"
    }
  ]
}